Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial

Journal of Infectious Diseases

Volumn 195, Issue 1, 2007, Pages 118-123

  Matee, Mecky ^a   Lahey, Timothy ^b   Vuola, Jenni M ^e,f   Mtei, Lillian ^a   Cole, Bernard F ^b   Bakari, Muhammad ^a   Arbeit, Robert D ^c   Horsburgh, C Robert ^d   Pallangyo, Kisali ^a   Von Reyn, C Fordham ^b,g  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d Transcept Pharmaceuticals Inc   (United States)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f GLAXOSMITHKLINE   (Finland)

^g DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; LIPOARABINOMANNAN; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM TUBERCULOSIS ANTIGEN 85; MYCOBACTERIUM VACCINE; SENSITIN; TUBERCULIN;

ADULT; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL LYSATE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; PRIORITY JOURNAL; TANZANIA; TUBERCULOSIS;

ADULT; BCG VACCINE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; LYMPHOCYTE ACTIVATION; MYCOBACTERIUM; TUBERCULIN TEST; TUBERCULOSIS;

EID: 33845646009     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/509896     Document Type: Article

References (17)

1. McConkey SJ, Reece WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9:729-35.
2. Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol 2005; 26:660-7.
3. McShane H, Hill A. Prime-boost immunisation strategies for tuberculosis. Microbes Infect 2005; 7:962-7.
4. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003; 171:1602-9.
5. Tanghe A, D'Souza S, Rosseels V, et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 2001; 69:3041-7.
6. McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-4.
7. Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367:938-40.
8. Ravn P, Boesen H, Pedersen BK, Andersen P. Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Guerin. J Immunol 1997; 158:1949-55.
9. Black GF, Weir RE, Floyd S, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002; 359:1393-401.
10. Vuola JM, Ristola MA, Cole B, et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS 2003; 17:2351-5.
11. Landay A, Ohlsson-Wilhelm B, Giorgi JV. Application of flow cytometry to the study of HIV infection. AIDS 1990; 4:479-97.
12. Kemp EB, Belshe RB, Hoft DF. Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guerin. J Infect Dis 1996; 174:113-9.
13. Johnson PD, Stuart RL, Grayson ML, et al. Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol 1999; 6:934-7.
14. Meyaard L, Otto SA, Hooibrink B, Miedema F. Quantitative analysis of CD4+ T cell function in the course of human immunodeficiency virus infection: gradual decline of both naive and memory alloreactive T cells. J Clin Invest 1994; 94:1947-52.
15. von Reyn CF, Vuola JM. New vaccines for the prevention of tuberculosis. Clin Infect Dis 2002; 35:465-74.
16. Elliott AM, Hodsdon WS, Kyosiimire J, et al. Cytokine responses and progression to active tuberculosis in HIV-1-infected Ugandans: a prospective study. Trans R Soc Trop Med Hyg 2004; 98:660-70.
17. Sutherland R, Yang H, Scriba TJ, et al. Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS 2006; 20:821-9.